CD8A and neoplasm: Cancer cells evade anti-tumor adaptive immune responses, in part, by downregulating MHC class I (MHC-I) molecules which are required for CD8+ cytotoxic T lymphocyte (CTL)-dependent activation and cytotoxicity.